UPDATED: FDA approves trailblazing postpartum depression therapy, in crucial milestone for women’s health – Endpoints News

In a landmark decision, the US health regulator has approved the first treatment for mothers suffering from postpartum depression (PPD), a common but often overlooked and stigmatized complication of childbirth that affects an estimated 1 in 7 women. The manufacturer of the injectable treatment — Sage Therapeutics — has been busy, raising more than half a billion dollars through the sale of its stock to support the commercial rollout of the drug, hiring a 180-strong salesforce and setting up select centers for women to get administered with the one-time treatment under medical supervision. In order to read this article, you ...

Gepostet in der Kategorie Lebensweise (Anzahl der ansichten:) 6

Ähnlich Nachrichten